Author of

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17598

    +

    P2.03a-042 - Comorbidity as a Prognostic Factor in Elderly Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy (ID 5851)

    14:30 - 14:30  |  Author(s): D.S. Sazdanic-Velikic
    • Abstract
    • Slides

    Background:
    The number of elderly lung cancer patients rises due to prolonged life expectancy, therefore the larger is proportion of patients with more comorbid conditions. The aim of this study is to evaluate influence of comorbidity on 2-year survival of elderly patients with advanced stage of non-small cell lung cancer treated with platinum-based chemotherapy.
    
    Methods:
    In our study we observed 152 elderly patients with patohistologicaly confirmed non-small cell lung cancer in advanced stage (IIIB, IV), treated with platinum-based chemotherapy, retrospectively. We evaluate the prognostic value of pretreatment comorbidity status on the 2-year survival.
    
    Results:
    Our analysis showed that the number of comorbid conditions (0-without, 1, 2, 3 comorbid conditions) didn’t statistically influence 2-year survival (p=0,894), but patients with more comorbid diseases have shorter 2-year survival (12.5% / 10.5% / 8.5% / 6.3% respectivelly). There were no statistically significant differences in 2-year survival according the value of Charlson index of comorbidity (p=0.312). There were no statistically differences in 2-year survival relative to the presence or absence of comorbid condition of particular systemic organs: respiratory (p=0.692), cardiovascular (p=0.382), gastronitestinal (p=0.657), diabetes (p=0.676), previous malignancy (p=0.586). Patients without respiratory comorbidity had better 2-year survival, but not significantly (Mantell/Cox p=0.0782).
    
    Conclusion:
    CONSLUSION: In strictly, by criteria selected, fit, elderly lung cancer patient comorbidity doesn’t significantly influence survival. Comorbidity should be a stimulus for treatment design rather than an exclusion criteria for oncologic treatment.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.